Individualized therapy options and strategies to predict treatment response for patients with mature T-cell leukemias/lymphomas. Funded by @ERANET_PerMed
Check out our submission for the @ERANET_PerMed video competition summarizing 3 years of work with the @JAKSTATtarget Consortium! Great video editing by our MSc student @bilalsaqib_. The winner will be decided by Youtube likes, so please like and share!
https://t.co/3ZPd1YtlfV
Ianevski et al. 2021, from the Aittokallio group at @FIMM_UH
Patient-tailored design for selective co-inhibition of leukemic cell subpopulations https://t.co/czcrPL0nwB
Adult-Onset Anti-Citrullinated Peptide Antibody-Negative Destructive Rheumatoid Arthritis Is Characterized by a Disease-Specific CD8+ T Lymphocyte Signature by Kelkka et al. 2020 from @hruh_research@TRIMMprogram
https://t.co/ZrZexjrOvE
Presenting some publications from work conducted by the JAK-STAT Target consortium
Reinstated p53 response and high anti-T-cell leukemia activity by the novel alkylating deacetylase inhibitor tinostamustine by Pützer et al. 2020 https://t.co/TkRp5jcONG
Stay up to date on more exciting research progress from this multidisciplinary initiative to advance new #JAKSTAT-targeted therapeutics for T-cell leukemias/lymphomas at the @JAKSTATtarget consortium website:
https://t.co/A3LHLRAxOQ
New publication from the project! The neonatal microenvironment programs innate γδ T cells through the transcription factor STAT5: https://t.co/qrzGKQK3MB
New version of #SynergyFinder, a widely used web-tool for interactive analysis and visualization of drug combination screening data, now available. Updated tool published by Group Aittokallio @FIMM_UH@HiLIFE_helsinki in @NAR_Open. #datascience https://t.co/OStezOQzNl
News from JAKSTAT-Target: New version of the SynergyFinder webtool available! New features support higher-order combination data analytics and exploratory visualization of multi-drug synergy patterns https://t.co/sbuaLoV6nd
This old Twitter account is now taken over by JAKSTAT-Target consortium project which aims to create individualized therapy options and strategies to predict treatment response for patients with mature T-cell leukemias/lymphomas
Apply now for the #CeMMPostdocProgram in Vienna, that includes two interesting potential projects in the group of Kaan Boztug, one focusing on Precision pediatric oncology and the other on Organoid-omics.
Everyone @LBI_CR wishes our followers a wonderful holiday season and a succesful New Year. The instute will be integrated into our partners @MedUni_Wien and @VetmeduniVienna, thus as of 2018 the institute comes to its scheduled end.
We had an exciting 14 years in a time cancer research saw fantastic developments. It was great to have the opportunitiy to contribute with the support of so many collaborators and partners. Thank you all for your support. But now it is time to say goodbye!
How is life on the cell surface? Many models and diagrams show the cell surface as stiff and unmovable barrier between cells and the outside. But imagine cell membranes are an extremely thin fluid layer of a fatty substance (lipids), which forms a barrier.
#biolution#cell
@richard_moriggl receives funding after positive evaluation of proposal for ERANET-PLL: high-quality, well-structured and viability highly supported by preliminary data #fwf